Pharmaceutical industry news
Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.
37,801 stories, page 231 of 631
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry
NCT07762703: Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.
ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry
NCT06597734: A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Study type: INTERVENTIONAL. Phase: PHASE2.
ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry
NCT06042478: Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
Study type: INTERVENTIONAL. Phase: PHASE3.
ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry
NCT03740165: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Study type: INTERVENTIONAL. Phase: PHASE3.
ClinicalTrials.govOriginal source






